There seems to be some debate about whether or not attaining 250 MACE would be considered a material event.  And thanks to KayakerBC we know how the TSX defines material, as something that could reasonably be expected to have a "significant" impact on the value of Resverlogix's shares and warrants.

So how do you think the market would react to a (strictly hypthetical 'what if') PR like this:

January 29, 2019

Resverlogix's Phase 3 BETonMACE trial reaches 250 MACE milestone

Calgary Alberta Canada and Sanfranciso California USA.  January 29, 2019 (Bogus Newswire) Resverlogix Corp (TSX RVX / OTC RVXCF) is pleased to announce that the Phase 3 BETonMACE trial is estimated to have attained the targeted 250 number of Major Adverse Cardiac Events (MACE) as specified in the trial's design.  BETonMACE began dosing in October of 2015 and the onset of the targeted number of MACE is an important milestone toward the completion of this potentially transformative study.

The company is providing guidance that top line results from BETonMACE should be released within the first half of 2019.  Yada yada yada.....

Am I alone in thinking that a PR of this nature could significantly move the market?